Welcome to our dedicated page for Glucotrack SEC filings (Ticker: GCTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GlucoTrack, Inc. filings document the regulatory, financial, and capital-structure disclosures of a medical technology company developing an implantable continuous blood glucose monitoring system for diabetes. Form 8-K reports cover Regulation FD releases on CBGM development, IDE-related disclosures, peer-reviewed study announcements, financial results, and corporate highlights.
The company’s filings also record material definitive agreements involving promissory-note exchanges for common stock, private-placement and exemption disclosures, beneficial-ownership limits, and shareholder voting matters. Proxy materials describe Nasdaq stock-issuance approvals, warrant-related share issuance proposals, meeting mechanics, governance procedures, and capital-structure matters tied to GlucoTrack’s public-company financing activities.
Glucotrack, Inc. is soliciting proxies for its 2026 virtual Annual Meeting to consider election of five directors and several corporate actions. Key matters include: (1) approval of up to a 1-for-30 reverse stock split (management may implement any ratio up to that aggregate), (2) a warrant inducement/repricing proposal to permit repricing and issuance of inducement warrants to support exercise of certain private placement warrants, and (3) ratification of CBIZ CPAs P.C. as independent auditors. The proxy discloses 6,259,279 shares issued and outstanding and lists outstanding derivative instruments including 2,198,301 warrants and 16,499 option shares (all figures stated as of June 16, 2026). The reverse split is presented as a tool to address Nasdaq bid-price compliance and would be executed only if management elects to do so within one year; fractional shares would be rounded up.
Glucotrack, Inc. has received two Nasdaq deficiency notices that together threaten its continued listing on The Nasdaq Capital Market. The first relates to failure to meet the $1.00 per share minimum bid price requirement under Nasdaq Rule 5550(a)(2). The second, based on its Form 10-Q for the period ended March 31, 2026, states the company no longer meets the $2,500,000 minimum stockholders’ equity requirement under Listing Rule 5550(b)(1) and does not qualify under alternative standards.
The company plans to timely request a hearing before a Nasdaq Hearings Panel by May 18, 2026, which will temporarily stay delisting while it presents a plan to regain compliance. The filing cautions there is no assurance the appeal will succeed or that Glucotrack will be able to regain or maintain compliance with Nasdaq listing rules.
GLUCOTRACK, INC. ownership disclosure: Armistice Capital, LLC and Steven Boyd report 102,115 shares, representing 4.99% of common stock, with shared voting and dispositive power over those shares. The filing states the Master Fund has the right to receive dividends or sale proceeds for the reported securities.
Glucotrack, Inc. reported a larger share count and ongoing losses as it advances development of its implantable continuous blood glucose monitor. For the quarter ended March 31, 2026, the company recorded a net loss of $4,334 thousand, with research and development expenses of $2,132 thousand and general and administrative expenses of $2,071 thousand.
Cash and cash equivalents fell to $3,929 thousand from $7,383 thousand at year-end, and accumulated deficit reached $156,172 thousand. Management states these factors raise substantial doubt about its ability to continue as a going concern and expects to rely on additional equity or debt financings. Subsequent events include an IDE submission to the FDA for a U.S. clinical study, equity raises under an ELOC facility, debt-for-equity exchanges, and a Nasdaq staff determination to delist the stock for failing the $1.00 bid-price rule, which the company plans to appeal.
Glucotrack, Inc. reported first quarter 2026 results showing a narrower net loss while advancing its implantable continuous blood glucose monitor program. Net loss was $4.3 million for the quarter, compared with $6.8 million a year earlier, mainly due to a smaller non-cash impact from derivative liabilities.
Research and development expenses were $2.1 million and general and administrative expenses were $2.1 million, both up from the prior year as the company invested in product, manufacturing and corporate infrastructure. Cash and cash equivalents were $3.9 million as of March 31, 2026, down from $7.4 million at December 31, 2025.
The company submitted an Investigational Device Exemption application to the FDA for its fully implantable continuous blood glucose monitoring technology and is targeting a U.S. clinical trial launch in the second half of 2026. Management expects existing cash to fund operations into early third quarter 2026, supporting initiation of the planned U.S. human clinical trial shortly thereafter.
Glucotrack, Inc. has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration to begin a U.S. clinical study of its fully implantable continuous blood glucose monitoring (CBGM) technology.
The system is designed as a long-term, blood-based continuous glucose monitor with no on-body wearable component and a sensor longevity of 3 years, aiming to provide real-time glucose data in a comfortable and discreet form. The IDE submission follows several years of engineering, preclinical evaluation, and iterative design work, and Glucotrack plans to proceed with the U.S. clinical study following FDA review and approval.
Glucotrack, Inc. entered into an Exchange Agreement to swap a $988,000 partitioned promissory note for 1,300,000 shares of its common stock. This is a debt-for-equity exchange with no cash paid by the investor, which reduces note principal while increasing the share count.
The issuance is subject to a 19.9% beneficial ownership limitation, so shares may be issued in tranches and any unexchanged portion of the note will remain outstanding. The company also furnished an updated investor presentation as an exhibit.
Glucotrack, Inc. reported new peer-reviewed data on its fully implantable continuous blood glucose monitoring (CBGM) system from an in-vivo ovine study. Thirty-four devices implanted in 17 adult sheep were followed for up to 240 days and achieved a weighted average Mean Absolute Relative Difference (MARD) of 6.8% across 79 intravenous glucose tolerance tests, indicating high accuracy, with no device-related adverse safety events observed.
The company noted that these preclinical results, together with prior first-in-human data showing a MARD of 7.7% with 99% data capture and no procedure- or device-related serious adverse events, help support its planned IDE submission to the FDA and continued clinical development of its long-life CBGM platform.
Glucotrack, Inc. files a Post-Effective Amendment to its Form S-1 registering up to 20,060,000 shares of Common Stock for resale by Sixth Borough Capital Fund, LP. The registration covers up to 20,000,000 Purchase Shares tied to a purchase agreement that could provide up to $20.0 million in committed equity financing and 60,000 Commitment Shares issuable on exercise of pre-funded warrants. As of April 27, 2026, Glucotrack had 3,659,279 shares outstanding and a last reported Nasdaq sale price of $0.72 per share. The company controls timing of any sales to Sixth Borough and would receive proceeds only if it elects to sell Purchase Shares under the Purchase Agreement.